Copy Number Variations Found in Patients with a Corpus Callosum Abnormality and Intellectual Disability

Solveig Heide, MD,1,2,3 Boris Keren, MD, PhD4, Thierry Billette de Valmelle, MD, PhD5,6,7, Sandra Chantot-Bastaraud, MD1, Christel Depienne, PhD1,2,4,8,9,10 Caroline Nava, MD, PhD3,4, Cyril Mignot, MD, PhD1, Aurélia Jacquette, MD1, Eric Fonteneau4, Elodie Lejeune6, Corinne Mach4, Isabelle Marey, MD,1 Sandra Whalen, MD11, Didier Lacombe, MD, PhD12, Sophie Naudion, MD12, Caroline Rooryck, MD, PhD12, Annick Toutain, MD, PhD13, Cédric Le Caignec, MD, PhD14, Damien Haye, MD15, Laurence Olivier-Faivre, MD, PhD16, Alice Masurel-Paulet, MD16, Christel Thauvin-Robinet, MD, PhD16, Fabien Lesne, CRA1, Anne Faudet, CRA1, Dorothée Ville, MD17, Vincent des Portes, MD, PhD17, Damien Sanlaville, MD, PhD18,19, Jean-Pierre Siffroi, MD, PhD18, Marie-Laure Moutard, MD5,6,7, and Delphine Héron, MD1,2,3,11

Objective To evaluate the role that chromosomal micro-rearrangements play in patients with both corpus callosum abnormality and intellectual disability, we analyzed copy number variations (CNVs) in patients with corpus callosum abnormality/intellectual disability

Study design We screened 149 patients with corpus callosum abnormality/intellectual disability using Illumina SNP arrays.

Results In 20 patients (13%), we have identified at least 1 CNV that likely contributes to corpus callosum abnormality/intellectual disability phenotype. We confirmed that the most common rearrangement in corpus callosum abnormality/intellectual disability is inverted duplication with terminal deletion of the 8p chromosome (3.2%). In addition to the identification of known recurrent CNVs, such as deletions 6qter, 18q21 (including TCF4), 1q43q44, 17p13.3, 14q12, 3q13, 3p26, and 3q26 (including SOX2), our analysis allowed us to refine the 2 known critical regions associated with 8q21.1 deletion and 19p13.1 duplication relevant for corpus callosum abnormality; report a novel 10p12 deletion including ZEB1 recently implicated in corpus callosum abnormality with corneal dystrophy; and) report a novel pathogenic 7q36 duplication encompassing SHH. In addition, 66 variants of unknown significance were identified in 57 patients encompassed candidate genes.

Conclusions Our results confirm the relevance of using microarray analysis as first line test in patients with corpus callosum abnormality/intellectual disability. (J Pediatr 2017;November;88-99).

The corpus callosum is the main commissure in the human brain connecting homotopic and heterotopic regions of the cerebral hemispheres.1 Corpus callosum abnormality is among the most common brain malformations, affecting 1 out of 4000 newborns2 and 2%-3% of individuals with intellectual disability.2,3,4 Three major classes of corpus callosum abnormality are distinguished: complete agenesis, partial agenesis, and dysgenesis.5 The corpus callosum abnormality may be associated with additional cerebral or extracerebral malformations or may be an isolated finding.6 Intellectual disability ranging from mild to severe, epilepsy, and behavioral difficulties7,8 are commonly associated with corpus callosum abnormality.

Genetic causes have been ascribed to 30-45% of corpus callosum abnormality, including chromosomal rearrangements (10%-20%) and mendelian conditions (30%).9,30 These causes are characterized by their extreme heterogeneity with more than 300 different causative genes identified to date.9 Over the past years, chromosomal analyses using microarray studies have identified numerous disease-causing copy number variations (CNVs) in multiple disorders, including

CNVs Copy number variations
DGV Database of genomic variants
NF1 Neurofibromatosis type 1
SHH Sonic hedgehog
VOUS Variants of unknown significance

From the 1APHP, GH Pitié-Salpêtrière, Department of genetics, unit of medical genetics, reference center for intellectual disabilities of rare causes, Paris, France; 2GRC Intellectual Disability and Autism, UPMC, Paris, France; 3Sorbonne Universities, UPMC Univ Paris 06, UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM, Paris, France; 4APHP, GH Pitié-Salpêtrière, Department of genetics, unit of developmental genomic, Paris, France; 5APHP, Hôpital Armand-Trousseau, Division of pediatric neurology, Paris, France; 6GRC Corrèa-Lévy, UPMC, Paris, France; 7Inserm U1141, Paris, France; 8APHP, Hôpital Armand-Trousseau, Department of genetics, division of chromosomal genetics, Paris, France; 9Department of translational medicine and neurogenetics, IBGMNC, CNRS UMR 7104/INSERM U946, Université de Strasbourg, Illkirch, France; 10Institute of medical genetics of Alsace, Division of cytogenetics, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; 11APHP, Hôpital Armand-Trousseau, Department of genetics, Division of clinical genetics, Hôpitaux Paris, France; 12CHU Bordeaux, Division of medical genetics, INSERM U1211, Université de Bordeaux, Bordeaux, France; 13Hôpital Bretonneau, CHU Tours, Division of genetics, Tours, France; 14CHU Nantes, Institute of biology, Division of medical genetics, Inserm UMR 915/CNRS ERL3147, Nantes, France; 15APHP, Hôpital Robert-Debré, Division of medical genetics, Paris, France; 16CHU Dijon, Hôpital d’enfants, FHU-TRANSLAD, Genetic Center, Dijon, France; 17HCL, GH Est, Division of pediatric neurology, Bron, France; 18HCL, Division of genetics, Bron, France; and 19Center of Research in neurosciences of Lyon, Inserm U1028, UMR CNRS 6250, GENDEV Team, Université Claude Bernard-Lyon 1, Lyon, France

Supported by the Assistance Publique des Hôpitaux de Paris (APHP), PHRC (n°P081260), the Fondation Maladies Rares, the Agence de la Biomédecine AOR 2012, the Agence Nationale de la Recherche (ANR Blanc 2013 CILAXCAL), and the “Investissements d’Avenir” program ANR-10-IDHU-06 (HU-A-ICM). S.H. is supported by a master grant from the Fondation pour la Recherche Médicale (FRM; DEA20150633232). The authors declare no conflicts of interest.

http://dx.doi.org/10.1016/j.jpeds.2017.02.023
syndromes with corpus callosum abnormality. O’Driscoll et al\textsuperscript{10} provided a first genetic map, including several genomic loci involved in corpus callosum development. These loci may contain genes in which variations cause or predispose to corpus callosum abnormality.

The purpose of this study was to investigate chromosomal rearrangements in a well-characterized French cohort of 149 patients with corpus callosum abnormality and intellectual disability using SNP microarrays. We report here known and new likely pathogenic CNVs with candidate genes.

**Methods**

Between 2009 and 2014, we ascertained prospectively 159 patients (from 3 to 41 years old), recruited in the French national study on corpus callosum abnormality/intellectual disability (Agénésie du Corps Calleux avec Retard Mental cohort). All parents signed an appropriate consent form for genetic analysis, in accordance with national ethic rules and recommendations of the National Heart, Lung and Blood Institute Working Group.\textsuperscript{11} This project was submitted to the appropriate ethics committee (Comité de Protection des Personnes Ile-de-France).

All patients had corpus callosum abnormality (partial or complete agenesis or dysgenesis of the corpus callosum) on brain magnetic resonance imaging (Figure) and intellectual disability or developmental delay for youngest patients. All brain magnetic resonance imaging were gathered in the coordinating center and ascertained collectively by a team comprising a radiologist, a neuropediatrician, and a geneticist to classify the corpus callosum abnormality into 3 categories: partial corpus callosum agenesis, complete corpus callosum agenesis, or dysgenesis of the corpus callosum. Complete corpus callosum agenesis was defined as the absence of corpus callosum, including the absence of any anatomic remnant, and partial corpus callosum agenesis as the absence of at least 1, but not all, regions of the corpus callosum. Dysgenesis of the corpus callosum was used to designate a complete corpus callosum (all anatomic regions are present) with an abnormal shape.\textsuperscript{5} Corpus callosum abnormality was considered as associated (associated corpus callosum abnormality) when another brain malformation and/or another extracerebral rare malformation was discovered. When no other malformation was detected, corpus callosum abnormality was considered as isolated (isolated corpus callosum abnormality).

Corpus callosum abnormality was diagnosed either during the prenatal period (n = 71, 44.5\%) or postnatally when the patients were referred for neuroimaging for neurodevelopmental delay or intellectual disability (n = 88, 55.5\%). In all patients with a prenatal diagnosis, corpus callosum abnormality was confirmed by postnatal neuroimaging performed after 2 years of age. All patients had a clinical evaluation by a geneticist and a pediatric neurologist at the time of inclusion. The

---

دریافت فوری
متن کامل مقاله

امکان دانلود نسخه تمام متن مقالات انگلیسی
امکان دانلود نسخه ترجمه شده مقالات
پذیرش سفارش ترجمه تخصصی
امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
امکان دانلود رایگان ۲ صفحه اول هر مقاله
امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
دانلود فوری مقاله پس از پرداخت آنلاین
پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات